ArticleNaunyn-Schmiedeberg's archives of pharmacology2026
Quarterly persistence as a signal prioritization framework in FAERS: an analysis of the 2025 public-use releases.
Article in Naunyn-Schmiedeberg's archives of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
To develop and apply a quarterly pharmacovigilance workflow for the 2025 FDA Adverse Event Reporting System (FAERS) public-use XML releases, with emphasis on temporal persistence, cohort sensitivity, and prioritization-oriented signal characterization. The raw input consisted of 12 quarterly FAERS XML files (approximately 8.58 GB), which were parsed into report-level drug-reaction pairs using a chunked workflow. The main analysis used a PS-clinical cohort including primary suspect drugs from serious reports, whereas a sensitivity analysis expanded this definition to a PS + SS-clinical cohort by including secondary suspect drugs. Quarterly product-reaction pairs were screened using a disproportionality rule requiring
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.